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a b s t r a c t 
The development of self-nanoemulsifying drug delivery systems (SNEDDS) to enhance the 
oral bioavailability of lipophilic drugs is usually based on traditional one-factor-at-a-time 
approaches. These approaches may be inadequate to analyse the effect of each excipient 
and their potential interactions on the emulsion droplet size formed when dispersing the 
SNEDDS in an aqueous environment. The current study investigates the emulsion droplet 
sizes formed from SNEDDS containing different levels of the natural surfactant monoacyl 
phosphatidylcholine to reduce the concentration of the synthetic surfactant polyoxyl 40 
hydrogenated castor oil (Kolliphor ® RH40). Monoacyl phosphatidylcholine was used in the 
form of Lipoid S LPC 80 (LPC, containing approximately 80% monoacyl phosphatidylcholine, 
13% phosphatidylcholine and 4% concomitant components). The investigated SNEDDS com- 
prised of long-chain or medium-chain glycerides (40% to 75%), Kolliphor ® RH40 (5% to 55%), 
LPC (0 to 40%) and ethanol (0 to 10%). D-optimal design, multiple linear regression, and par- 
tial least square regression were used to screen different SNEDDS within the investigated 
excipient ranges and to analyse the effect of each excipient on the resulting droplet size of 
the dispersed SNEDDS measured by dynamic light scattering. All investigated formulations 
formed nano-emulsions with droplet sizes from about 20 to 200 nm. The use of medium- 
chain glycerides was more likely to result in smaller and more monodisperse droplet sizes 
compared to the use of long-chain glycerides. Kolliphor ® RH40 exhibited the most significant 
effect on reducing the emulsion droplet sizes. Increasing LPC concentration increased the 
emulsion droplet sizes, possibly because of the reduction of Kolliphor ® RH40 concentration. 
A higher concentration of ethanol resulted in an insignificant reduction of the emulsion 
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droplet size. The study provides different ternary diagrams of SNEDDS containing LPC and 
Kolliphor ® RH40 as a reference for formulation developers. 
© 2017 Shenyang Pharmaceutical University. Published by Elsevier B.V. 
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 1. Introduction 
The use of modern drug discovery programs has increased the
number of new active pharmaceutical ingredients (API) with
high lipophilicity and poor oral absorption [1] . Lipid-based
drug delivery systems (LbDDS) have been used as one of the
most effective strategies to enhance the oral bioavailability
of these API [2] . The main rationale behind the utility of Lb-
DDS is that they usually present the drug in solution, thus by-
passing the dissolution step prior to absorption. At the same
time the lipid excipients may enhance drug solubilisation and
intestinal permeability and stimulate lymphatic transport in
the intestine [2–4] . Among the large variety of LbDDS, the
self-nanoemulsifying drug delivery systems (SNEDDS) are fre-
quently used for oral delivery of lipophilic drugs. SNEDDS are
mixture of glycerides, surfactants and co-solvent and spon-
taneously form nanoemulsions upon dispersion in aqueous
media. Due to the small droplet size of the dispersed SNEDDS,
lipid digestion and drug release from SNEDDS are less affected
by inter- and intra-personal variations, including food effect
[5] . 
The droplet size of the emulsion formed upon SNEDDS dis-
persion in aqueous environment depends on the type and
amount of surfactants and co-solvent used. Monoacyl phos-
phatidylcholine (Lipoid S LPC 80 (LPC)) has been recently
used as a natural lipophilic surfactant to significantly reduce
the emulsion droplet size of SNEDDS containing medium-
chain (MC) glycerides, caprylocaproyl polyoxyl-8 glycerides
(Labrasol ®), and ethanol [6] . However, using long-chain (LC)
glycerides instead of MC glycerides in these formulations re-
sulted in polydisperse emulsions with droplet sizes in the
micrometer range upon dispersion in a simulated intesti-
nal medium [6] . In an effort to formulate SNEDDS contain-
ing both LC glycerides and LPC, other hydrophilic surfactants
need to be considered to replace Labrasol ®. Kolliphor ® sur-
factants, in particular polyoxyl 40 hydrogenated castor oil
(Kolliphor ® RH40 (KOL)), have been used in SNEDDS contain-
ing LC glycerides to obtain nanoemulsions. Formulations con-
taining sesame oil, glyceryl monooleate (Peceol TM ), and KOL
(at a ratio of 25:27:48) or soybean oil, glyceryl monolinoleate
(Maisine TM 35-1), KOL, and ethanol (at a ratio of 25:25:40:10)
formed emulsion droplets of 30 ±1 and 41 ± 1 nm, respec-
tively, upon dispersion in water (at a ratio of 1:250) [7,8] . Be-
sides their emulsification capacity, Kolliphor ® surfactants are
permeation enhancers with P-glycoprotein inhibition activity
[3] making these excipients an important surfactant family to
investigate. Therefore, KOL may be a good candidate to com-
bine with both LC and MC glycerides and LPC to formulate
SNEDDS. 
Many SNEDDS have been developed with consideration
on the resulting emulsion droplet sizes after dispersion us- ing traditional one-factor-at-a-time approaches to construct
ternary diagrams [8–10] . This approach often provides inade-
quate data to analyse the effect of each excipient and their po-
tential interactions on the formulation performance. In addi-
tion, it does not always allow prediction outside or even within
the investigated ranges of excipients. Experimental design has
been recently applied in formulation development [11] . With
this approach, an optimal amount of information can be ob-
tained from a limited number of experiments [11–13] . More-
over, using an experimental design approach during initial
screening can provide more insight on excipient effects and
interactions on the selected response variables [14,15] . There-
fore, the objective of this study is to investigate the emul-
sion droplet size of different SNEDDS containing LPC, KOL and
ethanol, using an experimental design approach with focus on
maximising LPC level and minimising KOL level whilst main-
taining a small droplet size of the dispersed systems. 
2. Materials and methods 
2.1. Materials 
Lipoid S LPC 80 (LPC) (containing 80.8% soybean monoacyl
phosphatidylcholine (MAPC) and 13.2% phosphatidylcholine
(PC)) and Lipoid S PC (containing 98.0% pure soybean PC) were
provided by Lipoid GmbH (Ludwigshafen am Rhein, Germany).
Sodium taurodeoxycholate hydrate (NaTDC) ( > 95% pure), 2-
(N-morpholino)ethanesulfonic acid (MES) hydrate ( > 99.5%
pure), MES sodium salt ( > 99% pure), Trizma ® maleate, and
soybean oil were purchased from Sigma-Aldrich (St Louis,
MO, USA). Glyceryl monolinoleate (Maisine TM 35-1 (Maisine))
was a gift from Gattefossé (Saint-Priest, France). Polyoxyl 40
hydrogenated castor oil (KOL) was a gift from BASF (Lud-
wigshafen, Germany). Glyceryl tricaprylate/tricaprate (Captex
300 (Captex)) and glyceryl monocaprylate (Capmul MCM EP
(Capmul)) were provided by Abitec (Columbus, OH, USA). Ab-
solute ethanol (99.9%) and sodium chloride were obtained
from VWR (Radnor, PA, USA). Water was purified using a SG Ul-
traclear water system (SG Water GmbH, Barsbüttel, Germany).
2.2. Methods 
2.1.1. Design of experiments 
Two formulation sets containing either LC glycerides (soybean
oil: Maisine (1:1 w/w) or MC glycerides (Capmul: Captex (1:1
w/w)), LPC, KOL, and ethanol were studied. Experimental de-
sign was used to screen the effect of each excipient on the
emulsion droplet size of the dispersed formulation. The con-
centration ranges of excipients are variable, therefore a D-
optimal design was selected instead of a classical mixture de-
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Table 1 – Variables and levels used in the four D-optimal designs (DoE I – DoE IV). 
Formulation variables Levels 
DoE I DoE II DoE III DoE IV 
Low High Low High Low High Low High High 
X 1 : Glyceride fraction 0 .40 0 .40 0 .40 0 .40 0 .60 0 .60 0 .75 0 .75 
X 2 : KOL fraction 0 .30 0 .55 0 .15 0 .30 0 .05 0 .25 0 .05 0 .25 
X 3 : LPC fraction 0 0 .25 0 .25 0 .40 0 .05 0 .25 0 0 .2 
X 4 : Ethanol fraction 0 0 .10 0 0 .10 0 0 .10 0 0 .10 
Table 2 – Composition and droplet size and PdI value of resulting emulsions of the LC formulation set prepared based on 
DoE I. The sizes and PdI values are presented as mean ±SD (n = 3). 
Formulation Composition Appearance Z-average (nm) PdI 
X 1 X 2 X 3 X 4 
LC1 0.40 0 .55 0 .05 – + 26 ± 0 0.07 ± 0.01 
LC2 0.40 0 .35 0 .25 – +++ 100 ±0 0.37 ± 0.03 
LC3 0.40 0 .50 – 0 .10 + 34 ± 1 0.05 ± 0.01 
LC4 0.40 0 .30 0 .20 0 .10 ++ 43 ± 1 0.24 ± 0.00 
LC5 0.40 0 .533 – 0 .067 + 28 ± 1 0.05 ± 0.02 
LC6 0.40 0 .417 0 .183 – +++ 90 ± 5 0.38 ± 0.04 
LC7 0.40 0 .30 0 .217 0 .083 + 59 ± 1 0.23 ± 0.00 
LC8 0.40 0 .55 0 .017 0 .033 ++ 28 ± 1 0.05 ± 0.02 
LC9 0.40 0 .317 0 .25 0 .033 ++ 75 ± 1 0.25 ± 0.01 
LC10 0.40 0 .433 0 .067 0 .10 + 27 ± 1 0.07 ± 0.01 
LC11 0.40 0 .425 0 .125 0 .05 ++ 46 ± 1 0.22 ± 0.00 
LC12 0.40 0 .425 0 .125 0 .05 ++ 41 ± 0 0.23 ± 0.00 
LC13 0.40 0 .425 0 .125 0 .05 ++ 42 ± 1 0.22 ± 0.00 
X 1 : glyceride fraction, X 2 : KOL fraction, X 3 : LPC fraction, X 4 : ethanol fraction. 
+: transparent; ++: bluish; +++: turbid. 
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1ign [11] . Details of independent variables and their levels in 
he investigated formulations are shown in Table 1 . 
A D-optimal design with 13 experiments, including 3 cen- 
re points, was generated for the two formulation sets con- 
aining 40% glycerides, 30%–55% KOL, 0–25% LPC, and 0–10% 
thanol (design of experiment (DoE) I) ( Table 1 ) by MODDE 
1.0.2 software (Umetrics, Sweden). The LPC level was limited 
o 25% when combining LPC with LC glycerides and 40% when 
ombining LPC with MC glycerides. These maximum levels 
ere fixed because of the high viscosity of LPC-containing Lb- 
DS [6] and the limited capacity of LPC to homogenously dis- 
erse in the lipid matrix. Table 2 shows the compositions of 
he DoE I formulations. The resulting emulsion droplet sizes 
f these formulations were evaluated by dispersing them in a 
edium simulating human fasted-state intestinal fluid (Fast- 
dM) [16] and measuring the droplet sizes of the formed emul- 
ions using a dynamic light scattering technique (described 
elow). Based on the feasibility of LPC incorporation and the 
esulting emulsion droplet sizes of DoE I formulations, further 
nvestigations with higher LPC and glyceride concentrations 
ere then performed with DoE II (containing 25%–40% LPC),
oE III (containing 60% glycerides), and DoE IV (containing 75% 
lycerides). The objectives were to maximize LPC concentra- 
ion and investigate the capacity of LPC and KOL to efficiently 
mulsify high glyceride levels. The levels of the formulation 
ariables in DoE II, III and IV are shown in Table 1 . Tables 4, 5,nd 6 show the compositions of formulations in DoE II, III, and 
V, respectively. 
.1.2. Cryogenic transmission electron microscopy studies 
he droplets formed by dispersing the formulation in Fast- 
dM were investigated by cryogenic transmission electron mi- 
roscopy (Cryo-TEM). Three microlitre of the samples were 
arefully injected on a Lacey carbon film grid (Ted Pella Inc.,
edding, CA, US). The grids were blotted in a Vitrobot auto- 
ated vitrification device (FEI, Eindhoven, The Netherlands) 
nder controlled environmental conditions (25 °C, 100% rel- 
tive humidity), automatically plunged into liquid ethane to 
reeze the samples and then transferred to liquid nitrogen.
he frozen samples were then transferred to a Gatan 626 cry- 
holder (Gatan Inc., Pleasanton, CA, USA) coupled to a FEI 
ecnai G2 transmission electron microscope (FEI, Eindhoven,
he Netherlands). The samples were observed under low-dose 
ondition at −174 °C. Images were recorded by a FEI Eager 4k 
CD camera (FEI, Eindhoven, The Netherlands). 
.1.3. Droplet size measurements 
he droplet sizes of the emulsions formed when dispers- 
ng the formulations in FastedM was measured to evalu- 
te the emulsification capacity of the formulations. FastedM 
ontains 2.63 mM NaTDC, 0.23 mM PC, 3.25 mM MES hydrate,
1.50 mM MES sodium salt, and 109.75 mM sodium chloride, at 
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 pH 6.6 ± 0.1 [16] . The formulations were dispersed in FastedM
at a ratio of 1:200 (v/v) and gently mixed at 20 rpm and 37 °C for
5 min using an Intelli-Mixer RM-2M rotator (ELMI, Riga, Latvia).
The droplet size of the formed emulsion was measured by dy-
namic light scattering (DLS) at 37 °C using a Zetasizer Nano
ZS (Malvern, Worcestershire, UK) (173 o backscattering an-
gle, 0.686 cP sample viscosity). Three independent samples
of each formulation were investigated for each measurement.
The particle sizes are reported as the mean z-average values
(i.e. particle sizes calculated based on the signal intensity) and
the polydispersity is expressed as polydispersity index (PdI)
values. 
2.1.4. Data analysis 
The effect of each excipient concentration on the emulsifica-
tion capacity and the interaction between excipients were in-
vestigated by correlating the matrix of excipient concentra-
tions to the matrix of measured emulsion droplet sizes us-
ing the MODDE 11.0.2 software. These data were fitted to a
quadratic equation: 
 = β0 + β2 X 2 + β3 X 3 + β4 X 4 + β22 X 2 2 + β33 X 2 3 + β44 X 2 4 + β23 X 2 X 3
+ β24 X 2 X 4 + β34 X 3 X 4 (Eq. 1
where the response Y is the real or the transformed value of
the emulsion droplet size, the variables X 2 , X 3 , X 4 are the frac-
tions of KOL, LPC and ethanol, respectively, expressed in a 0–
1 range, β0 , β2 , β3 , β4 , β22 , β33 , β44 , β23 , β24 , β34 are equation
coefficients. The model is reliable when the goodness of fit (R 2 )
is close to 1, and the goodness of prediction (Q 2 ) is larger than
0.5 [11] . 
3. Results and discussion 
The emulsification capacity of formulations with different ex-
cipient concentrations was evaluated to investigate the utility
of KOL, LPC, and ethanol in combination with glycerides to for-
mulate SNEDDS. The emulsification capacity was compared
between LC and MC formulations. Based on the models rep-
resenting the relationship between excipient concentrations
and emulsion droplet sizes, the effects of each excipient on
the emulsion droplet size were analysed. Fig. 1 – Cryo-TEM images of emulsions obtained from dispersing
(at a ratio of 1:200). 3.1. Emulsification capacity of LC formulations 
containing LPC and KOL 
The structures formed upon dispersion of LC formula-
tions of DoE I in FastedM at a ratio 1:200 (v/v) were ob-
served by Cryo-TEM ( Fig. 1A ) and measured the size by
DLS ( Table 2 ). Nanoemulsion droplets were the only particle
species found in the obtained colloidal systems confirming
the self-nanoemulsification capacity of the formulations. The
obtained droplet sizes of 13 emulsions were fitted to Eq. 1 to
analyse the effect of each excipient on the emulsion droplet
size formed. The coefficients of the fitted quadratic model are
shown in Table 3 . 
All LC formulations of DoE I generated nanoemulsions with
mean emulsion droplet sizes ranging from 26 to 100 nm and
PdI values from 0.05 to 0.38 ( Table 2 ). The appearance of the
emulsions formed agreed with the size of the oil droplets:
emulsions with droplet sizes from 26 to 34 nm were transpar-
ent, emulsions with droplet sizes from 43 to 59 nm were bluish
and emulsions with droplet sizes from 100 to 124 nm were tur-
bid. The results confirm that all investigated LC formulations
from DoE I were SNEDDS. 
After fitting the droplet sizes of the thirteen LC SNEDDS of
DoE I to Eq. 1 using multiple linear regression, the coefficients
were calculated and are shown in Table 3 . Statistically insignif-
icant coefficients, i.e. ß44 , ß23 , ß24 , and ß34 were eliminated.
The R 2 and Q 2 values of the fitted model are 0.93 and 0.82, re-
spectively, suggesting a satisfactory goodness of fit and predic-
tivity of the model. The statistically significant coefficients of
the fitted equation were ß2 , ß3 , ß4 , ß22 , and ß33 , corresponding
to the concentration of KOL, LPC, and ethanol and the square
terms of KOL and LPC levels ( Table 3 ). Based on the significance
of these formulation factors, the effect of KOL, LPC and ethanol
concentrations on the resulting emulsion droplet size was sig-
nificant. The effect of each component on the resulting droplet
size was analysed by predicting the droplet size from SNEDDS
with concentration of each excipient (KOL or LPC or ethanol)
varying from its lowest to highest level (30%–55% KOL, 0–25%
LPC, and 0–10% ethanol) while maintaining the ratio of other
two excipients as in a reference formulation. The reference
formulation contains glycerides:KOL:LPC:ethanol (at a ratio of
40:42.5:12.5:5 w/w) as it was selected at the centre point of (A) LC7 (see Table 2 ) and (B) MC34 (see Table 6 ) in FastedM 
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Table 3 – Regression coefficients of the fitted quadratic models ( Eq. 1 ) for the different experimental designs. 
Coefficient Variable Formulation set 
LC MC 
DoE I DoE I & II DoE III DoE IV 
ß0 – 42 0.48 0.49 1.34 
ß2 X 2 (KOL) 125 a −0.08 a −0.37 a −0.31 a 
ß3 X 3 (LPC) −159 a 0.16 a 0.34 a 0.31 a 
ß4 X 4 (Ethanol) 85 a −0.02 0.05 0.22 a 
ß22 X 2 ∗X 2 −120 a 0.02 a 0.05 a –
ß33 X 3 ∗X 3 147 a 0.10 a 0.10 a –
ß44 X 4 ∗X 4 − 0.01 0.09 –
ß23 X 2 ∗X 3 − −0.10 a −0.13 a –
ß24 X 2 ∗X 4 − 0.01 0.04 –
ß34 X 3 ∗X 4 − −0.03 −0.14 a –
Transformation None Logarithm Logarithm Logarithm 
Method Multiple linear 
regression 
Partial least square 
regression 
Partial least square 
regression 
Partial least square 
regression 
R 2 0.93 0.92 0.98 0.89 
Q 2 0.82 0.86 0.67 0.70 
X 1 : glyceride fraction, X 2 : KOL fraction, X 3 : LPC fraction, X 4 : ethanol fraction. 
a Signifies significant coefficient. 
Fig. 2 – Factor effect plots showing the effect of each component on the nanoemulsion droplet size from (A) LC SNEDDS of 
DoE I and (B) MC SNEDDS of DoE I & II. The displayed droplet sizes are the predicted values obtained when varying one 
excipient concentration (KOL, LPC or ethanol) and maintaining the ratio of the other excipients as in a reference 
formulation. The reference formulation is the centre point, containing KOL:LPC:ethanol (at a ratio of 42.5:12.5:5 w/w for (A) 
and 35:20:5 w/w for (B)). A 40% glyceride concentration is fixed for all formulations. 
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c  he constrained region of DoE I. The predicted droplet sizes 
re plotted in Fig. 2A to analyze the excipient effect on the 
esulting emulsion droplet sizes. The fitted model suggests 
hat KOL and ethanol have a significant effect on reducing the 
anoemulsion droplet sizes while a high LPC concentration 
esults in increased droplet sizes of the resulting nanoemul- 
ions. 
The fitted model provided a prediction plot for the droplet 
ize of the emulsions from the LC formulation set ( Fig. 3A ).
ll LC formulations in the investigated range were predicted 
o generate nanoemulsions in FastedM. Increasing KOL and 
thanol and reducing LPC concentration in LC formulations Ohifted the obtained nanoemulsions to the area of smaller 
roplet sizes in the predicted ternary diagram ( Fig. 3A ). With 
0%–25% LPC, LC SNEDDS are semi-solid and formed emul- 
ions with high polydispersity index (higher than 0.2); there- 
ore LC SNEDDS with LPC level higher than 25% were not in- 
estigated. 
.2. Emulsification capacity of MC formulations 
ontaining LPC and KOL 
C formulations containing LPC and KOL were prepared ac- 
ording to the compositions suggested by DoE I to IV ( Table 1 ).
il-in-water emulsion droplets were the only species ob- 
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Fig. 3 – (A) Prediction plot of LC SNEDDS containing 40% LC glycerides (soybean oil:Maisine (1:1 w/w)), 30–55% KOL, 0–25% 
LPC, and 0–10% ethanol (DoE I). (B) Prediction plot of MC SNEDDS containing 40% MC glycerides (Captex:Capmul (1:1 w/w)), 
15–55% KOL, 0–40% LPC, and 0–10% ethanol (DoE I & II). Excipient concentrations are presented as fractions. 
Table 4 – Composition and droplet size and PdI value of resulting emulsions of the MC formulation set prepared based on 
DoE I (MC1 to MC13) and DoE II (MC14 to MC22). The sizes and PdI values are presented as mean ±SD (n = 3). Absence of 
an SD value for z-average signifies SD < 0.5. 
Formulation Composition Appearance Z-average (nm) PdI 
X 1 X 2 X 3 X 4 
MC1 0.40 0.55 0.05 – + 18 0.07 ±0.01 
MC2 0.40 0.35 0.25 – + 19 0.09 ±0.01 
MC3 0.40 0.50 – 0.10 + 21 0.08 ±0.00 
MC4 0.40 0.30 0.20 0.10 + 18 0.11 ±0.01 
MC5 0.40 0.533 – 0.067 + 20 0.05 ±0.01 
MC6 0.40 0.417 0.183 – + 19 0.09 ±0.00 
MC7 0.40 0.30 0.217 0.083 + 18 0.11 ±0.01 
MC8 0.40 0.55 0.017 0.033 + 20 0.10 ±0.05 
MC9 0.40 0.317 0.25 0.033 + 21 0.21 ±0.01 
MC10 0.40 0.433 0.067 0.10 + 18 0.06 ±0.01 
MC11 0.40 0.425 0.125 0.05 + 17 0.08 ±0.02 
MC12 0.40 0.425 0.125 0.05 + 17 0.09 ±0.01 
MC13 0.40 0.425 0.125 0.05 + 17 0.17 ±0.02 
MC14 0.40 0.30 0.30 – + 23 0.10 ±0.01 
MC15 0.40 0.30 0.25 0.05 + 19 0.13 ±0.00 
MC16 0.40 0.20 0.40 – + 32 0.11 ±0.01 
MC17 0.40 0.15 0.40 0.05 ++ 40 0.25 ±0.01 
MC18 0.40 0.25 0.20 0.10 + 19 0.13 ±0.01 
MC19 0.40 0.15 0.35 0.10 + 26 0.20 ±0.00 
MC20 0.40 0.225 0.325 0.05 + 23 0.17 ±0.00 
MC21 0.40 0.225 0.325 0.05 + 23 0.17 ±0.00 
MC22 0.40 0.225 0.325 0.05 + 23 0.17 ±0.00 
X 1 : glyceride fraction, X 2 : KOL fraction, X 3 : LPC fraction, X 4 : ethanol fraction. 
+: transparent; ++: bluish; +++: turbid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 served when dispersing MC SNEDDS in FastedM using cryo-
TEM ( Fig. 1B ). For DoE I, MC formulations formed transpar-
ent emulsions with droplet sizes ranging from 17 to 21 nm
and PdI values ranging from 0.06 to 0.17 ( Table 4 ). The droplet
sizes from MC SNEDDS were smaller and more homogeneous
as seen from the lower PdI values compared to those from
LC SNEDDS of the same composition ratios ( Table 2 ). There
were no significant differences between the emulsion droplet
sizes of all MC formulations in DoE I. It can therefore be
concluded that MC formulations containing 30%–55% KOL
formed monodisperse nanoemulsions with droplet sizes ofapproximately 20 nm without a significant influence of LPC
and ethanol levels. The small emulsion droplet sizes of MC
formulations in DoE I suggests the possibility of formulating
MC SNEDDS with lower KOL concentrations and higher LPC or
glycerides concentrations. These excipient ranges were inves-
tigated in DoE II, DoE III and DoE IV ( Table 1 ) to maximise LPC
level and to investigate the capacity of LPC and KOL to emul-
sify high glyceride levels. 
Compared to DoE I, MC formulations in DoE II contained
lower KOL levels and higher LPC levels, while the glyceride
level was kept constant. LPC was unable to be dispersed at
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Table 5 – Composition and droplet size and PdI value of resulting emulsions of the MC formulation set prepared based on 
DoE III. The sizes and PdI values are presented as mean ±SD (n = 3). 
Formulation Composition Appearance Z-average (nm) PdI 
X 1 X 2 X 3 X 4 
MC23 0.60 0 .25 0 .15 – + 23 ± 1 0.06 ± 0.01 
MC24 0.60 0 .25 0 .05 0.10 + 27 ± 1 0.05 ± 0.01 
MC25 0.60 0 .15 0 .25 – ++ 70 ± 2 0.44 ± 0.00 
MC26 0.60 0 .05 0 .25 0.10 +++ 169 ± 5 0.32 ± 0.02 
MC27 0.60 0 .25 0 .10 0.05 + 23 ± 1 0.04 ± 0.01 
MC28 0.60 0 .10 0 .25 0.05 ++ 53 ± 1 0.25 ± 0.00 
MC29 0.60 0 .15 0 .15 0.10 + 27 ± 1 0.09 ± 0.01 
MC30 0.60 0 .175 0 .175 0.05 + 26 ± 1 0.09 ± 0.01 
MC31 0.60 0 .175 0 .175 0.05 + 26 ± 1 0.11 ± 0.01 
MC32 0.60 0 .175 0 .175 0.05 + 25 ± 0 0.11 ± 0.01 
X 1 : glyceride fraction, X 2 : KOL fraction, X 3 : LPC fraction, X 4 : ethanol fraction. 
+: transparent; ++: bluish; +++: turbid. 
Fig. 4 – Factor effect plots showing the effect of each component on the nanoemulsion droplet size from MC SNEDDS – (A) 
DoE III and (B) DoE IV. The displayed droplet sizes are the predicted values obtained when varying one excipient 
concentration (KOL or LPC or ethanol) and maintaining the ratio of the other excipients as in a reference formulation. The 
reference formulation contains KOL:LPC:ethanol (at a ratio of 17.5:17.5:5 w/w for (A) and 13:8:4 w/w for (B)). A 60% glyceride 
concentration is fixed for all formulations of DoE III and a 75% glyceride concentration is fixed for all formulations of DoE IV. 
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iigher concentrations than 40% in MC lipid matrix and high 
PC levels resulted in high formulation viscosity [6] . The emul- 
ions obtained from the MC formulations of DoE II were trans- 
arent or slightly bluish with droplet sizes varying in a narrow 
ange from 19 to 40 nm and PdI values varying in a narrow 
ange from 0.10 to 0.25, signifying monodisperse nanoemul- 
ions. When fitting the emulsion droplet size and excipient 
oncentration from both DoE I and DoE II to Eq. 1 , the ob-
ained R 2 and Q 2 of the fitted equation were 0.92 and 0.86,
espectively. Based on the coefficient values ( Table 3 ), increas- 
ng KOL concentrations resulted in reduced emulsion droplet 
izes while increasing LPC concentration resulted in larger 
mulsion droplet sizes, as also shown in the factor effect plots 
 Fig. 2B ) and ternary diagram ( Fig. 3B ), albeit in a narrow size
ange. 
To study the capacity of LPC and KOL to emulsify higher MC 
lyceride concentrations than 40%, DoE III was designed with 
he extended glyceride range up to 60%. The resulting emul- 
ion droplet sizes (from 23 to 169 nm) and PdI values (from .04 to 0.44) of MC SNEDDS of DoE III are shown in Table 5 . For
oE III, MC formulations containing high glyceride and low 
OL concentrations formed larger emulsion droplet sizes (e.g.
C25 and 26). The fitted model obtained for DoE III has R 2 and
 
2 values of 0.98 and 0.67, respectively. Fig. 4A presents the 
ain effect of each excipient on the droplet sizes for DoE III.
his effect was evaluated by predicting the droplet sizes from 
ifferent SNEDDS with varied concentrations of one excipient 
KOL or LPC or ethanol) and a constant ratio of other two ex-
ipients. The ratio of those two excipients was kept as in a ref-
rence formulation containing glycerides:KOL:LPC:ethanol (at 
 ratio of 60:17.5:17.5:5 w/w). Increasing the KOL concentration 
educed the emulsion droplet size, whilst increasing LPC from 
5% to 25% resulted in an opposite effect and ethanol exhib- 
ted an insignificant effect on the droplet size ( Fig. 4A ). Increas- 
ng LPC concentration between 5% to 15% did not result in a 
ignificant effect on droplet size, possibly because of the high 
OL concentrations. Changing KOL concentrations resulted 
n more significant variation of emulsion droplet sizes com- 
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Fig. 5 – (A) Prediction plot of MC SNEDDS containing 60% glycerides (Captex:Capmul (1:1 w/w)), 5%–25% KOL, 5%–25% LPC, 
and 0–10% ethanol (DoE III). (B) Prediction plot of MC SNEDDS containing 75% glycerides (Captex:Capmul (1:1 w/w)), 5%–25% 
KOL, 0–20% LPC, and 0–10% ethanol (DoE IV). Excipient concentrations are presented as fractions. 
Table 6 – Composition and droplet size and PdI value of resulting emulsions of the MC formulation set prepared based on 
DoE IV. The sizes and PdI values are presented as mean ±SD (n = 3). 
Formulation Composition Appearance Z-average (nm) PdI 
X 1 X 2 X 3 X 4 
MC33 0.75 0.25 – – + 36 ±0 0.05 ±0.00 
MC34 0.75 0.05 0.2 – +++ 175 ±1 0.19 ±0.01 
MC35 0.75 0.15 – 0.1 ++ 57 ±0 0.16 ±0.01 
MC36 0.75 0.05 0.15 0.05 +++ 187 ±2 0.18 ±0.01 
MC37 0.75 0.2 – 0.05 ++ 46 ±0 0.13 ±0.01 
MC38 0.75 0.125 0.125 – ++ 51 ±1 0.16 ±0.00 
MC39 0.75 0.1 0.1 0.05 ++ 58 ±1 0.09 ±0.01 
MC40 0.75 0.1 0.1 0.05 ++ 56 ±1 0.09 ±0.01 
MC41 0.75 0.1 0.1 0.05 ++ 62 ±1 0.09 ±0.01 
X 1 : glyceride fraction, X 2 : KOL fraction, X 3 : LPC fraction, X 4 : ethanol fraction. 
+: transparent; ++: bluish; +++: turbid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 pared to changing LPC and ethanol concentrations ( Fig. 4A ).
The predicted droplet size of formulations within the investi-
gated range is plotted in the ternary diagram in Fig. 5A , which
shows that emulsion droplet sizes increased for SNEDDS with
high LPC and low KOL concentrations. 
Based on small emulsion droplet size formed from MC
SNEDDS of DoE III, it was possible to investigate the capacity of
LPC and KOL to emulsify higher MC glycerides levels than 60%.
The MC glyceride concentration was thus increased up to 75%
in DoE IV ( Table 1 ) for this purpose. Opaque emulsions with
emulsion droplet sizes of approximately 200 nm were found in
SNEDDS containing 5% KOL (i.e. MC34 and 36), while transpar-
ent emulsions with a small droplet size of about 20 nm were
found in SNEDDS containing a high KOL concentration (e.g.
MC33) ( Table 6 ). All resulting emulsions were monodisperse
with PdI < 0.2 [17] . A main effect plot of DoE IV was constructed
to analyse the effect of each excipient on the resulting droplet
sizes ( Fig. 4B ). The main effect plot was based on the droplet
size prediction for SNEDDS with varied concentrations of one
excipient (KOL or LPC or ethanol) while keeping the concen-
tration of other two excipients at a constant ratio. The excip-
ient ratio was from a reference formulation containing glyc-
erides:KOL:LPC:ethanol (at a ratio of 75:13:8:4 w/w). The fitted model for DoE IV has an R 2 = 0.89 and Q 2 = 0.70. KOL is sug-
gested to have a positive effect on reducing emulsion droplet
size while adding LPC and ethanol had a negative effect on
droplet size reduction. Increasing LPC and ethanol concentra-
tions increased emulsion droplet sizes possibly because this
reduced KOL concentration. In Fig. 5B , the ternary diagram
presenting the predicted emulsion droplet sizes from SNEDDS
of DoE IV shows that the droplet sizes were indeed reduced in
the area with high KOL and low LPC and ethanol concentra-
tions. 
3.3. Effect of excipients on the emulsion droplet size 
Lipid chain length had a substantial influence on the emul-
sion droplet sizes formed by dispersing SNEDDS in FastedM.
SNEDDS containing 40% glycerides formed smaller emulsion
droplet sizes when replacing LC by MC glycerides. A simi-
lar effect of fatty acid chain length on emulsion droplet size
was observed by Thomas et al [8] . MC glycerides were more
favourable to form smaller emulsion droplet sizes than the
corresponding LC glycerides because shorter fatty acid chains
relate to higher hydrophilicity [18] . Increasing MC glyceride
concentrations from 40% to 75% resulted in larger emulsion
droplet sizes. All emulsions formed by MC SNEDDS within the
544 Asian Journal of Pharmaceutical Sciences 13 (2018) 536–545 
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rnvestigated ranges were predicted to be monodisperse with 
ean droplet sizes below 200 nm. The effect of increasing LC 
lyceride concentration on the emulsion droplet size was not 
nvestigated because LC6 with the lowest investigated LC glyc- 
ride concentration of (i.e. 40%) already formed a polydisperse 
mulsion. 
According to Tran et al., combining LC glycerides with 
abrasol ®, LPC and ethanol resulted in polydisperse coarse 
mulsions when the formulations were dispersed in FastedM 
6] . Replacing Labrasol ® by KOL and keeping the other compo- 
ents at the same concentrations resulted in monodisperse 
anoemulsions. Smaller emulsion droplet sizes were obtained 
rom MC glycerides containing KOL instead of Labrasol ®. KOL 
an reduce nanoemulsion droplet sizes better than Labrasol ®,
ossibly because of the chemical structure of KOL with more 
olyethylene glycol groups and therefore higher hydrophilic- 
ty than Labrasol ®. This is also expressed by the higher 
ydrophilic-lipophilic balance (HLB) value of KOL (HLB = 14–
6) compared to Labrasol ® (HLB = 12) [19,20] . 
In the current study, to analyse the overall effect of dif- 
erent excipient concentrations on the resulting emulsion 
roplet sizes from different MC SNEDDS, all data from DoE I 
o IV were fitted together in one model. The obtained model 
ad an R 2 of 0.91 and a Q 2 of 0.72. The ternary diagrams, corre- 
ponding to different excipient concentrations, are presented 
n Fig. S1 (Supporting Information) to facilitate the compar- 
son. Varying the KOL and LPC ratio resulted in significantly 
ifferent size distribution of the emulsions. Increasing KOL 
oncentration caused smaller emulsion droplet sizes. The use 
f 20% KOL guarantees the formation of nanoemulsions with 
roplet sizes smaller than 40 nm when being dispersed in 
astedM, while using only 5% KOL results in bluish or turbid 
anoemulsions with droplet sizes larger than 70 nm. In gen- 
ral, increasing LPC concentrations led to emulsions of larger 
roplet sizes. But with MC SNEDDS containing 40%–60% glyc- 
rides, varying LPC level between 5% and 15% did not affect 
he emulsion droplet sizes because of high KOL concentra- 
ion present. This effect is in contrast to the significant ef- 
ect of LPC on reducing emulsion droplet sizes formed from 
C SNEDDS containing Labrasol ® instead of KOL. Combining 
hese two findings, it is suggested that LPC reduces the emul- 
ion droplet sizes less effectively than KOL but more effec- 
ively than Labrasol ®. Since the effect of LPC on droplet sizes 
as governed by the KOL concentration, increased LPC con- 
entration (i.e. reduced KOL concentration) might increase the 
esulting droplet sizes. 
No substantial effect of ethanol on the nanoemulsion 
roplet size was observed in both LC and MC SNEDDS ( Fig. 3 
nd 5 ), which agrees with the previously found insignificant 
ffect of ethanol in a system containing soybean oil or rape- 
eed oil, KOL, Maisine and ethanol [12] . Comparing the ternary 
iagrams of SNEDDS containing 0 and 10% ethanol ( Fig. S1 ), in- 
reased ethanol concentration resulted in an insignificant re- 
uction of the nanoemulsion droplet size and the presence of 
thanol was not essential to the formation of nanoemulsions 
rom both LC and MC SNEDDS. . Conclusion 
-optimal design was used to facilitate the screening pro- 
ess of SNEDDS within wide ranges of glycerides, KOL, LPC 
nd ethanol concentrations, based on the resulting emulsion 
roplet sizes when dispersing the formulations in a medium 
imulating human fasted-state intestinal fluid. All formula- 
ions formed nanoemulsions with droplet sizes from 20 to 
00 nm. LPC can be incorporated at concentration of up to 
5% in LC SNEDDS and 40% in MC SNEDDS. With LPC and 
OL combined, LC glycerides can be incorporated at concen- 
ration of up to 40%, while MC glyceride concentration could 
e increased up to 75%. LC SNEDDS formed emulsions with 
arger and more polydisperse droplets than MC SNEDDS. KOL 
xhibited a strong impact on reducing nanoemulsion droplet 
izes making emulsification enhancement effect of LPC and 
thanol insignificant. The study provides a database of emul- 
ion droplet sizes from SNEDDS containing LPC with insights 
nto the emulsification effect of each excipient, which should 
e considered when selecting optimal formulation strategies.
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